Motilal Oswal reiterates ’buy’ rating for Max Healthcare, expects 15% upside
Live MintDomestic brokerage, Motilal Oswal Financial Services, reiterates 'buy' rating for Max Healthcare with a target price of ₹660, and sees an potential upside of 15% for the stock from Wednesday's close price of ₹575. Max Healthcare's share price is presently trading at 24x FY25E enterprise value /earnings before interest, taxes, depreciation, and amortisation, according to the brokerage, which is higher than the company's historical average of 22x. The report states that in FY23/1QFY24, Max Healthcare's EBITDA per bed was ₹6.4 m/ ₹6.7 m. EBITDA per bed for Rainbow Childrens Medicare Ltd in FY23/1QFY24 was ₹6.0/6.6 m, placing it second overall. "However, we expect Max Healthcare to continue trading at a premium on relative basis, backed by: a) significant land bank availability in high-demand areas of Delhi for brownfield expansion, b) focused approach to improve profitability per bed, and c) proven capability of strong turnaround of hospital assets," the brokerage said in its report.